TEVA
Teva Pharmaceutical Industries Ltd.
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · IL
$38.98
−0.54%Jul 14, 2026, 13:16 UTC
A U.S. appeals court revived a lawsuit by Teva Pharmaceuticals accusing Eli Lilly of breaching a settlement agreement that allowed Teva to market a generic version of Lilly's osteoporosis drug Forteo.
Source:Jul 12, 2026, 22:02 UTC
Teva Pharmaceutical Industries announced encouraging 24-week efficacy results from a phase 1b proof-of-concept study of its anti-IL-15 antibody for vitiligo, highlighting the program as part of its shift toward a biopharma-focused growth strategy.
Source:Jul 9, 2026, 13:00 UTC
Teva and Polpharma Biologics announced a global licensing agreement for a biosimilar candidate to Ocrevus (ocrelizumab) for multiple sclerosis.
Source:Jul 1, 2026, 12:30 UTC
The U.S. Supreme Court unanimously ruled in favor of generic drug manufacturers in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., reversing the Federal Circuit and setting a new standard for induced patent infringement claims.
Source:Jun 18, 2026, 20:57 UTC
Teva Pharmaceutical Industries submitted a New Drug Application (NDA) to the U.S. FDA for ecopipam, a therapy for pediatric Tourette syndrome.
Source:Jun 10, 2026, 16:03 UTC
Teva Pharmaceutical Industries closed its acquisition of Emalex Biosciences, strengthening its late-stage neuroscience pipeline with ecopipam.
Source:
← PreviousPage 2